LITS - NASDAQ

Lite Strategy, Inc.

LITS·NASDAQ

$1.43

-3.5%

HealthcareBiotechnology

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$52.60M

EPS-2.3900

P/E Ratio-1.89

Earnings Date02/11/2026

lits

Total Assets

Last Annual Value

18.29M

3-Year CAGR

-53%

5-Year CAGR

-36%

10-Year CAGR

-20%

Adjust for Inflation

Lite Strategy, Inc. Competitors Analysis of Total Assets

LITS · NASDAQ

Company	Total Assets	CAGR 3Y	CAGR 5Y	CAGR 10Y
Lite Strategy, Inc. NASDAQ:LITS	18.29M	-46.7%	-36.3%	N/A
Relmada Therapeutics, Inc. NASDAQ:RLMD	94.00M	-1.2%	-15.9%	41.9%
TScan Therapeutics, Inc. NASDAQ:TCRX	228.79M	-5.6%	4.0%	N/A
Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV	129.72M	-2.1%	4.0%	N/A
Clene Inc. NASDAQ:CLNN	18.13M	-29.8%	-22.1%	N/A
Prelude Therapeutics Incorporated NASDAQ:PRLD	141.31M	-20.2%	-14.3%	N/A
Unicycive Therapeutics, Inc. NASDAQ:UNCY	49.13M	51.3%	21.3%	N/A
Vaxart, Inc. NASDAQ:VXRT	186.08M	26.5%	-3.4%	16.6%
Adicet Bio, Inc. NASDAQ:ACET	192.35M	-2.5%	-10.7%	-9.8%
PMV Pharmaceuticals, Inc. NASDAQ:PMVP	116.56M	-22.7%	-18.9%	N/A
Werewolf Therapeutics, Inc. NASDAQ:HOWL	69.40M	-26.5%	-17.3%	N/A

Lite Strategy, Inc. Fair Value Envelope

LITS · NASDAQ

Our analysis suggests that LITS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.43, this represents a potential HIDDEN relative to our calculated worth for Lite Strategy, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.43

Related Guides

Blog Categories

Continue your LITS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.